Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Genetic testing in women with ovarian cancer helps determine prognosis

A study examining mutations in DNA repair genes in women with advanced ovarian cancer found that the disease remained at bay longer in women with the mutations than without, and that women having cancers with these mutations lived longer.

24 Mar 2016

Targeted therapies suppress T cell activity that could actually help fight tumors

In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations.

23 Mar 2016

Mutated gene GT198 has strong potential in early diagnosis of breast cancer

When mutated, a gene known for its ability to repair DNA, appears to instead cause breast cancer, scientists report.

21 Mar 2016

Ovarian serous cancer patients with overexpression of HER4 protein less likely respond to chemotherapy

Moffitt Cancer Center researchers discovered that patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival.

21 Mar 2016

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Research from Rutgers Cancer Institute of New Jersey examining difficult to treat cancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in the body.

18 Mar 2016

Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.

15 Mar 2016

Use of contralateral prophylactic mastectomy tripled from 2002 to 2012 despite no survival benefit

The use of contralateral prophylactic mastectomy (CPM), the surgical removal of a breast unaffected by cancer as part of the course of treatment for breast cancer, has more than tripled from 2002 to 2012 despite evidence suggesting no survival benefit over breast conservation, according to a new study from Brigham and Women's Hospital published in Annals of Surgery on March 11, 2016.

14 Mar 2016

Clinical review examines benefit of RT in breast cancer patients with BRCA1, BRCA2 mutations

In light of conflicting and inconclusive clinical data on the benefit of radiation therapy in cancer patients with the BRCA1 and BRCA2 mutation, a clinical review examined the current status of data regarding BRCA1 and BRCA2 deficiency and radiation therapy sensitivity and a potential strategy to intensify the effects of radiation therapy (RT) by poly(ADP-ribose) polymerase inhibitors (PARPi), the pharmacologic drugs under investigation as monotherapy for the treatment of breast cancer in patients with BRCA1 and BRCA2 mutations.

9 Mar 2016

IOM report elucidates state of ovarian cancer incidence, treatment and research

Ovarian cancer, one of the deadliest malignancies, is actually a constellation of different cancers that may originate in other organs and should not be treated as a single disease, concludes a new congressionally mandated report on the state of ovarian cancer incidence, treatment and research. The report, published by the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine, also highlights persistent serious disparities in delivery of care across different groups of women in the U.S., and suggests promising areas for further research.

4 Mar 2016

Psychological difficulties of ovarian cancer: an interview with Katherine Taylor

Ovarian cancer affects around 7000 thousand women in the UK every year and very sadly the outcomes are not great. A women dies every 2 hours of ovarian cancer. If I am diagnosed today, I’ve only got a 40% chance of being alive in 5 years’ time.

4 Mar 2016

Mapping family health history could drive patients to more timely screenings

Most doctors and nurses review a patient's family history to identify risk factors for heart disease and cancer, often through a paper checklist or brief interview.

4 Mar 2016

Differences in certain type of small protein may shed light on lung cancer risk in different races

Research from an investigator at Rutgers Cancer Institute of New Jersey and colleagues from the National Cancer Institute and other facilities, shows differences in a certain type of small protein vary by race and may contribute differently to the development of lung cancer in African Americans and European Americans.

3 Mar 2016

Oncimmune partners with Stroke Detection Plus to offer EarlyCDT-Lung test

Oncimmune, a leader in early cancer detection, today announced a partnership with Stroke Detection Plus® (SDP), a leading provider of cardiovascular and corporate wellness screenings in the US. Stroke Detection Plus and its wellness division, Health Gauge, will offer Oncimmune's EarlyCDT-Lung test to its clients which include large employers, unions and individuals.

3 Mar 2016

Researchers aim to develop gentler treatment that 'tricks' cancer cells

The most common treatments for cancer are radiation and chemotherapy. However they have side effects and also damage healthy tissues. Moreover, their effectiveness is limited when the cancer has spread through out the body. Researchers at the Niels Bohr Institute are therefore working to develop a gentler treatment that 'tricks' the cancer cells, which would absorb a cytotoxin and therefore be destroyed, while healthy cells would remain unaffected. The results are published in the scientific journal, Scientific Reports.

2 Mar 2016

Women struggling to find their voice: March 2016 ovarian cancer awareness month

Worrying new stats show almost 1 in 3 unable to talk about physical health issues with a doctor.

29 Feb 2016

Research unveils standard front-line treatment for advanced ovarian cancer

Research led by a Dignity Health St. Joseph's Hospital and Medical Center physician on ovarian cancer was published in the Feb. 24, 2016 issue of New England Journal of Medicine. The research was directed by Bradley J. Monk, M.D. and researchers at 12 other medical facilities around the nation.

27 Feb 2016

Investigating mechanism behind development of high-grade serous ovarian cancer

Rutgers Cancer Institute of New Jersey researcher Michael L. Gatza, PhD, has received a $747,000 Pathway to Independence Award (R00-CA166228) from the National Cancer Institute to explore the mechanism behind the development of a subtype of ovarian cancer known as high-grade serous ovarian cancer.

24 Feb 2016

Combining pain medicine with metal ions could destroy drug-resistant cancer cells

Fighting chemoresistant cancer remains a huge challenge that scientists are tackling from as many angles as they can. One alternative approach involves pairing two groups of compounds -- pain medicine and metal ions -- that have individually shown promise as anti-cancer agents. Scientists report in the ACS journal Inorganic Chemistry that combining the two led to new compounds that could destroy drug-resistant cancer cells and leave most normal cells alone in lab tests.

18 Feb 2016

Researchers reveal inherited genetic mutations associated with ovarian cancer risk

Previous research has established a link between genetic mutations in the BRCA1 and BRCA2 genes to an increased risk of developing ovarian, fallopian tube or peritoneal cancer in women.

11 Feb 2016

IDMC recommends continuation of PM1183 Phase III trial in platinum-resistant ovarian cancer patients

PharmaMar announced today that the Independent Data Monitoring Committee has notified the Company of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian cancer patients should continue without any changes.

8 Feb 2016

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Genetic testing in women with ovarian cancer helps determine prognosis

Targeted therapies suppress T cell activity that could actually help fight tumors

Mutated gene GT198 has strong potential in early diagnosis of breast cancer

Ovarian serous cancer patients with overexpression of HER4 protein less likely respond to chemotherapy

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Use of contralateral prophylactic mastectomy tripled from 2002 to 2012 despite no survival benefit

Clinical review examines benefit of RT in breast cancer patients with BRCA1, BRCA2 mutations

IOM report elucidates state of ovarian cancer incidence, treatment and research

Psychological difficulties of ovarian cancer: an interview with Katherine Taylor

Mapping family health history could drive patients to more timely screenings

Differences in certain type of small protein may shed light on lung cancer risk in different races

Oncimmune partners with Stroke Detection Plus to offer EarlyCDT-Lung test

Researchers aim to develop gentler treatment that 'tricks' cancer cells

Women struggling to find their voice: March 2016 ovarian cancer awareness month

Research unveils standard front-line treatment for advanced ovarian cancer

Investigating mechanism behind development of high-grade serous ovarian cancer

Combining pain medicine with metal ions could destroy drug-resistant cancer cells

Researchers reveal inherited genetic mutations associated with ovarian cancer risk

IDMC recommends continuation of PM1183 Phase III trial in platinum-resistant ovarian cancer patients

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in